Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2221 to 2235 of 9102 results

  1. Trastuzumab deruxtecan for adjuvant treatment of high-risk HER2-positive residual invasive breast cancer after neoadjuvant chemotherapy [ID6509]

    Awaiting development Reference number: GID-TA11658 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Zibotentan–dapagliflozin for treating chronic kidney disease with proteinuria [TSID12423]

    Awaiting development Reference number: GID-TA12474 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. COLOFIT model to guide colorectal cancer pathway referral in primary care: early use assessment

    In development Reference number: GID-HTG10862 Expected publication date: TBC

    HealthTech guidance
    In development

  4. Advanced breast cancer: diagnosis and management (Partial update)

    In development Reference number: GID-NG10430 Expected publication date: TBC

    NICE guideline
    In development

  5. Pimicotinib for treating tenosynovial giant cell tumours when systemic treatment is needed [ID6647]

    In development Reference number: GID-TA11859 Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Bepirovirsen with nucleoside or nucleotide analogues for treating chronic hepatitis B [ID6608]

    In development Reference number: GID-TA11803 Expected publication date:  10 March 2027

    Technology appraisal guidance
    In development

  7. Pulsed Field Ablation for Atrial Fibrillation

    Awaiting development Reference number: GID-HTG10866 Expected publication date: TBC

    HealthTech guidance
    Awaiting development

  8. Brentuximab vedotin in combination for untreated advanced classical Hodgkin lymphoma [ID6437]

    In development Reference number: GID-TA11516 Expected publication date:  06 May 2027

    Technology appraisal guidance
    In development

  9. Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma after 2 or more systemic treatments (review of TA677) [ID6325]

    In development Reference number: GID-TA11545 Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Baloxavir marboxil granules for treating and preventing influenza in people 3 weeks and over [TSID12432]

    Awaiting development Reference number: GID-TA12479 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Percutaneous thrombectomy for intermediate-risk and high-risk acute pulmonary embolism

    In development Reference number: GID-HTG10169 Expected publication date:  07 April 2027

    HealthTech guidance
    In development

  12. Larotrectinib for treating NTRK fusion-positive advanced solid tumours (MA review of TA630) [ID6292]

    In development Reference number: GID-TA11565 Expected publication date:  18 November 2026

    Technology appraisal guidance
    In development

  13. Venous thromboembolism in over 16s : aspirin following orthopaedic surgery (update)

    In development Reference number: GID-NG10469 Expected publication date: TBC

    NICE guideline
    In development

  14. MMprofiler for estimating risk in newly diagnosed multiple myeloma

    In development Reference number: GID-HTG10153 Expected publication date:  06 May 2027

    HealthTech guidance
    In development

  15. Durvalumab with platinum-based chemotherapy, then with or without olaparib, for treating newly diagnosed advanced or recurrent endometrial cancer [ID6317]

    In development Reference number: GID-TA11340 Expected publication date: TBC

    Technology appraisal guidance
    In development